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ABSTRACT
Purpose. We determined the prognostic value of carci-
noembryonic antigen (CEA) clearance after tumor
resection with serial evaluation of postoperative CEA
levels in rectal cancer.
Methods. Between 1994 and 2004, we retrospectively
reviewed 122 patients with rectal cancer whose serum CEA
levels were measured on the preoperative day and postop-
erative days 7 and 30. Patients with preoperative CEA levels
\5.0 ng/ml were excluded. An exponential trend line was
drawn using the three CEA values. Patients were categorized
into three groups based on R2 values calculated through trend
line, which indicates the correlation coefficient between
exponential graph and measured CEA values: exponential
decrease group (group 1: 0.9 \ R2 B 1.0), nearly exponen-
tial decrease group (group 2: 0.5 \ R2 B 0.9), and
randomized clearance group (group 3: 0.5 B R2). We then
analyzed the CEA clearance pattern as a prognostic
indicator.
Results. With a median follow-up of 57 months, the 5-year
overall survival was 62.3% vs. 48.1% vs. 25% and the
5-year disease-free survival was 58.6% vs. 52.7% vs. 25%
among groups 1, 2, and 3 (P = 0.014, P = 0.027, respec-
tively) in patients with stage III rectal cancer. For those with
stage II rectal cancer, the 5-year overall survival rate of
group 1 was significantly better than groups 2 and 3 (88.8%
vs. 74.1%, respectively, P = 0.021).
Conclusions. The postoperative pattern of CEA clearance
is a useful prognostic determinant in patients with rectal
cancer. Patients with a randomized pattern of CEA clearance
after tumor resection should be regarded as having the pos-
sibility of a persistent CEA source and may require
consideration of intensive follow-up or adjuvant therapy.
The major prognostic determinant of colorectal cancer
(CRC) is the pathologic stage of the tumor. Since 1987, the
American Joint Committee on Cancer (AJCC) and the
International Union Against Cancer (UICC) have proposed
a worldwide categorization of cancer staging based on
localized tumor invasion depth, nodal involvement, and the
status of metastasis (TNM).1 However, a recent analysis
has suggested that CRC is heterogeneous in survival pat-
terns even within staging categories.2,3 Thus, there have
been many efforts to determine the prognostic significance
of subgroup stratification in staging patients with node-
positive CRC, including molecular and biochemical
markers.4–6 However, the validity of those markers remains
controversial and their clinical application is limited due to
their complexity, the difficulties of standardization, and the
cost of measurement. Carcinoembryonic antigen (CEA) is
the most widely used and readily available tumor marker
for the management of CRC and quantitative measure-
ments of serum CEA can be performed easily and cost
effectively. Many clinical scientists have evaluated the
kinetic patterns of tumor markers as prognostic variables
and have discovered that there are characteristic patterns of
exponential changes in the tumor marker levels after sur-
gical resection or tumor recurrence.5–8,9–11
In this study, we assessed the pattern of serum CEA
clearance after radical colectomy by evaluating the postop-
erative CEA levels to determine its potential application as a
surrogate maker for predicting cancer-specific mortality.
PATIENTS AND METHODS
A total of 368 patients with stage II and III rectal cancer,
whose serum CEA levels were measured preoperatively and
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on postoperative days 7 and 30, were selected using the
rectal cancer database at Severance Hospital, Yonsei Uni-
versity Healthcare System. Data were collected from
between June 1994 and October 2004 and were corrected
prospectively. All of the serum CEA assays were performed
within one laboratory by the Elecsys 2010 electrochemi-
luminescence immunoassay (Roche Diagnostics GmbH,
Mannheim, Germany) in which the reference cutoff line was
5 ng/ml. Forty-three patients who underwent preoperative
chemotherapy or radiation therapy were excluded because
their preoperative serum CEA levels may have been influ-
enced by neoadjuvant treatment. From the remaining
patients, we further excluded 203 patients whose preopera-
tive CEA value was \5 ng/ml. We considered a group of
patients with serum CEA values \5 ng/ml as a subgroup
with non-CEA-producing tumors, and therefore, there was
no need to calculate the CEA clearance for this group in this
particular study. Following these exclusions, a total of 122
patients with stage II and III rectal cancer were analyzed.
Pathological Analysis
Standardized pathologic analysis was performed on all
of the specimens collected via radical rectal resection. The
rectal tumor was staged according to the 6th UICC TNM
staging system. Resection specimens were evaluated for
depth of tumor penetration, lymph node involvement, his-
tological type, and lymphovascular invasion.
Follow-Up
Patients received follow-up every 3 months for the first
3 years after surgery, every 6 months for the next 2 years,
and yearly thereafter. Follow-up examinations, including
clinical history, physical examination, serum CEA levels,
chest x-ray, abdominopelvic CT or MRI, and colonoscopy,
were performed. Positron emission tomography (PET)
scanning was used if necessary. Determination of recur-
rence was made by clinical and radiological examinations
or by histological confirmation.
Calculation of CEA Clearance
The serum CEA of every patient was measured at the
same time points before and after tumor resection. Peri-
operative serum CEA was collected and measured at three
different time points, including a preoperative value and
values on postoperative days 7 and 30. Because more fre-
quent sampling is very difficult in postoperative patients,
the time points were carefully chosen based on tumor cell
biology. The first CEA measurement was a preoperative
value intended to reflect aggressive tumor activity. The
second CEA measurement obtained on postoperative day 7
correlated with the average circulatory half-life of CEA,
and the third measurement collected on postoperative day
30 approximated the CEA wash-out phase.11–15
Because of the nature of CEA, decay and production have
an exponential distribution depending on the state of tumor
activity. As such, many researchers have used the natural log
transformation of tumor marker values over time to plot a
scatter graph.9,10 In this study, we chose the exponential
curve drawn by using the trend line, which is used in
demographic research and also biochemical marker study.15
The preoperative CEA values correspond to the starting
point of the exponential graph and CEA levels from post-
operative days 7 and 30 correspond to the half-life value and
the primary end point of this study, respectively (Fig. 1).
Our initial hypothesis held that if there was no source of
CEA production after tumor resection, the serum CEA
level should be cleared following an exponential kinetics
format. If the slope no longer follows exponential kinetics
and instead has a randomized pattern of clearance, then one
must suspect the possibility of a persistent source of CEA,
perhaps in the form of hidden metastasis or the regrowth of
remnant tumors due to the failure of complete tumor
resection. Using the trend line, R2 values were calculated
(Fig. 1). R2 indicates the correlation coefficient between
the trend line illustrating the exponential decrease and
measured CEA values. If R2 = 1, all data points fall on the
exponential line. Therefore, the closer the R2 value is to 1,
the more the CEA values tend to fit the exponential curve.
We categorized groups using the R2 value to facilitate
easier interpretation. We categorized the R2 values twice
because there is no ideal cutoff value. First, we divided the
patients into three groups: (1) exponential decrease group
(group 1: 0.9 \ R2 B 1), (2) nearly exponential decrease
group (group 2: 0.5 \ R2 B 0.9), and (3) randomized
clearance group (group 3: R2 B 0.5). We next divided
patients into two groups: (1) exponential decrease group
(group I: 0.9 \ R2 B 1.0), and (2) nonexponential decrease
group (group II: 0.9 \ R2). For stage II rectal cancer, there
were an insufficient number of cases belonging to Group 3,
and therefore, we were unable to perform separate analyses
of the tri-category variable.
The degree of slope (gradient) was calculated using the
exponential trend line (value q, Y = px-q) (Fig. 1b). The
gradient is illustrative of the velocity of clearance, acutely
vs. slowly decreased. We also categorized the gradient into
three groups: gradient B 0.4 (slow rate of decline);
0.4 \ gradient B 0.7 (moderate rate of decline); 0.7 \
gradient (rapid rate of decline).
Finally, we analyzed the CEA clearance patterns and the
gradients as prognostic factors and determined the onco-
logic outcomes between the patients with exponential CEA
clearance kinetics and those with nonexponential CEA
clearance kinetics.
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Statistical Analysis
Statistical evaluation was performed using the statistical
package SPSS for Windows (Version 11.0; SPSS Inc.,
Chicago, IL). Univariate disease-free survival (DFS) rates
and overall survival (OS) rates were calculated with the
Kaplan-Meier method for categorized variables. Univariate
survival analysis was conducted with the Cox regression
hazards model for R2 values. Multivariate survival analysis
was conducted with the Cox proportional hazards model.
The Cox proportional hazards model was generated by a
forward stepwise selection of variables, and a P value of
0.1 was adopted as the limit for inclusion of a covariant.
DFS and OS curves were calculated with the Kaplan-Meier
method. P \ 0.05 was considered statistically significant.
RESULTS
Patient Characteristics
A summary of patient characteristics is presented in
Table 1. The mean age was 57.56 ± 12.24 years. Fifty-
four patients (44.3%) with stage II rectal cancer and 68
patients (55.7%) with stage III rectal cancer were included.
The mean preoperative CEA value was estimated to be
28.73 (range, 5.03–447.20) ng/ml. The mean CEA value on
postoperative day 7 was 6.77 (range, 0.20–55.00) ng/ml,
and the mean CEA value on postoperative day 30 was 3.34
(range, 0.10–39.21) ng/ml. The R2 ranged from 0.02 to
1.00.
Disease-Free Survival and Overall Survival According
to Stratified R2 Values
The median follow-up period was 57.61 (range, 4–167)
months. In stage II rectal cancer, the Cox regression
method demonstrated that the R2 value was not signifi-
cantly related to DFS but was significantly associated with
OS (P = 0.339, P = 0.021, respectively). With catego-
rized evaluation of the R2 values, group I (exponential
decrease group) had 4.18 times better OS compared with
group II (hazards ratio (HR) 4.186; 95% confidence inter-
val (CI), 1.121–5.635; P = 0.033; Table 2). In stage III
rectal cancer, the R2 value was significantly associated with
both DFS and OS (P = 0.016, P = 0.004; respectively;
Table 3). With categorized evaluation of R2 values, group
1 (exponential decrease group) had 3.12 times better DFS
(95% CI, 1.14–8.542, P = 0.027) and 3.812 times better
OS compared with group 3 (randomized clearance group)
(HR, 3.812; 95% CI, 1.555–9.347; P = 0.003; Table 3).
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FIG. 1 CEA values (preoperative, postoperative day 7, postoperative
day 30) over time (a). An exponential trend line was drawn using each
CEA value. R2 values were calculated as the deviation between
calculated curves and the measured CEA value. The function of the
exponential curve also was calculated (Y = pX-q). The value ‘‘q’’
represents the gradient; it refers to the acute or slow decrease in CEA
following tumor resection (b)
TABLE 1 Patient characteristics
N = 122
Age (yr) 57.56 ±12.24
Sex
Female 46 (37.7%)
Male 76 (62.3%)
UICC 6th TNM stage
Stage II 54 (44.3%)
Stage III 68 (55.7%)
Preoperative mean CEA 28.73 (5.03–447.20)
POD 7 mean CEA (ng/ml) 6.77 (0.20–55.00)
POD 30 mean CEA (ng/ml) 3.34 (0.10–39.21)
Mean gradient (value ‘‘q’’) 0.6050 (-0.0639–3.07)
R2 value 0.8778 (0.02–1.00)
CEA carcinoembryonic antigen; POD postoperative day
R2 value and gradient (value ‘‘q’’) were calculated through trend line
illustrating exponential decrease (Y = px-q). R2 values indicate the
correlation coefficient between exponential graph and measured CEA
values and the gradient (value ‘‘q’’) is illustrative of the velocity of
clearance. The greater values ‘‘q’’ tended to show more rapid decline
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In stage II rectal cancer, the 5-year OS rates in groups I
and II were 88.8% and 74.1%, respectively (P = 0.021;
Fig. 2a) and the 5-year DFS rates in groups I and II were
78.4% and 64.8%, respectively (P = 0.167; Fig. 2b). In
stage III rectal cancer, the 5-year OS rates in groups I and
II were 62.3% and 38.7%, respectively (P = 0.039;
Fig. 3a). The 5-year DFS rates were 58.6% vs. 41.6%
between two groups (P = 0.098; Fig. 4a). The 5-year OS
rates were 62.3% vs. 48.1% vs. 25% among groups 1, 2,
and 3 (P = 0.014; Fig. 3b). The 5-year DFS rates were
58.6% vs. 52.7% vs. 25%, respectively among groups
(P = 0.027; Fig. 4b).
Prognostic Factors for Disease-Free Survival
and Overall Survival in Stage III Rectal Cancer
In stage III, one set of univariate analysis demonstrated
that pathologic N stage and CEA value on postoperative
day 30 were significantly associated with the DFS rates
(P = 0.032, P = 0.028, respectively). This result was
confirmed by multivariate analysis with both N stage and
R2 value (P = 0.033, P = 0.02; Table 4). Another set of
univariate analysis indicated that the pathologic N stage
and CEA value on postoperative days 7 and 30 were
associated with OS rates (P = 0.003, P = 0.003,
P = 0.005, respectively). This result was confirmed by
multivariate analysis with N stage, R2 value, and CEA
value on postoperative day 7 (P = 0.023, P = 0.002,
P = 0.013, respectively; Table 4).
Gradients
The gradients did not prove to be significant factors in
DFS or OS in stage II rectal cancer (P = 0.942, P = 0.721,
respectively; Table 2) and stage III rectal cancer
(P = 0.527, P = 0.551, respectively; Table 3). With cat-
egorized evaluation of gradients, the gradients were
significantly related to the preoperative CEA level but,
again, were not a significant factor of OS (P \ 0.001,
P = 0.537, respectively; Fig. 5).
DISCUSSION
This study illustrates how intimately related the clinical
behaviors of carcinomas and the survival rates are to the
biochemical kinetics of tumor markers immediately after
tumor resection. Many oncologic researchers have inves-
tigated the role of serum CEA as a prognostic indicator in
CRC.16–19 Some have focused primarily on the prognostic
value of preoperative CEA levels, whereas others have
focused solely on postoperative CEA values. Before this
study, our group demonstrated the utility of CEA values as
a prognostic indicator in rectal cancer. In that study, we
categorized three groups using preoperative and postoper-
ative day 7 CEA values. Group A included patients with
normal CEA levels (B5 ng/mL) in both the pre- and
postoperative periods, group B was comprised of patients
with elevated preoperative and normal postoperative CEA
levels, and group C included patients with persistently
elevated CEA levels during both periods. Patients with
stage III rectal cancer in group C demonstrated higher
systemic recurrence and worse 5-year survival rates com-
pared with the other groups.20
In this study, we sought to determine the prognostic
value of CEA clearance after tumor resection with serial
evaluation of postoperative CEA levels in those patients
with an elevated preoperative CEA. First, we evaluated the
R2 values as a prognostic indicator, which was calculated by
drawing exponential trend lines using serial CEA values.
Our data showed that patients with greater R2 values tended
to have better OS rates and better DFS rates in stages II and
III rectal cancer. Using the R2 value, we performed two
separate categorizations to evaluate survival rate. With both
categorizations, the results were the same: the exponential
decrease group had significantly better survival compared
with the nonexponential decrease groups in both stages II
TABLE 2 Cox regression with R2 value and gradient in stage II rectal cancer
Disease-free survival Overall survival
HR 95% Cl P value HR 95% CI P value
R2 value 0.252 0.015–4.247 0.339 0.055 0.004–0.768 0.021
R2 (cutoff)
0.9–1.0 (group I) 1.724 0.517–5.753 0.376 4.186 1.121–15.63 0.033
0.3–0.9 (group II) 1 1
Gradient (value ‘‘q’’) 1.045 0.316–3.460 0.942 1.284 0.326–5.063 0.721
HR hazards ratio; CI confidence interval
R2 value and gradient (value ‘‘q’’) were calculated through trend line illustrating exponential decrease (Y = px-q). Group I is the exponential
decrease group, and group II is the nonexponential decrease group. Group 1 is the exponential decrease group, group 2 is the nearly exponential
decrease group, and group 3 is the randomized clearance group. The gradient (value ‘‘q’’) is illustrative of the velocity of clearance
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and III rectal cancer. In stage III rectal cancer, there was a
significant difference in the 5-year OS rates (62.3% vs.
48.1% vs. 25%; P = 0.014) and in 5-year DFS between
groups (5-year DFS rates were 58.6% vs. 52.7% vs. 25%;
P = 0.027) among the exponential decrease, nearly expo-
nential decrease, and randomized clearance groups. We
hypothesized that when there is no longer a tissue source
producing CEA, the CEA levels would be washed out with a
TABLE 3 Cox regression with R2 value and gradient in stage III rectal cancer
Disease-free survival Overall survival
HR 95% Cl P value HR 95% CI P value
R2 value 0.178 0.044–0.722 0.016 0.154 0.043–0.555 0.004
R2(triple)
0.9–1.0 (group 1) 3.121 1.140–8.542 0.027 3.812 1.555–9.347 0.003
0.5–1.0 (group 2) 1.454 0.567–3.728 0.436 1.355 0.532–3.451 0.141
0.3–0.5 (group 3) 1 1
R2 (cutoff)
0.9–1.0 (group I) 1.720 0.795–3.719 0.168 2.111 1.021–4.366 0.044
0.3–0.9 (group II) 1 1
Gradient (value ‘‘q’’) 0.527 0.156–1.778 0.302 0.551 0.175–1.736 0.309
HR hazards ratio; CI confidence interval
R2 value and gradient (value ‘‘q’’) were calculated through trend line illustrating exponential decrease (Y = px-q). Group I is the exponential
decrease group, and group II is the nonexponential decrease group. Group 1 is the exponential decrease group, group 2 is the nearly exponential
decrease group, and group 3 is the randomized clearance group. The gradient (value ‘‘q’’) is illustrative of the velocity of clearance
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FIG. 2 The survival curves
according to the R2 value in stage
II rectal cancer. Group I
represents the exponential
decrease group compared with
group II, the nonexponential
decrease group. a There was a
significant difference between the
two groups in OS (P = 0.021). b
There was no statistically
significant difference between the
groups in DFS (P = 0.167)
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FIG. 3 The overall survival (OS) curves according to the R2 value in
stage III rectal cancer. Group I was the exponential decrease group
compared with group II, the nonexponential decrease group. a There
was a significant difference between the two groups (P = 0.039). The
group also was divided to three subgroups: group 1 was the
exponential decrease group; group 2 was the nearly exponential
decrease group; and group 3 was the randomized clearance group. b
Group 3 had significantly worse OS than group 1 (P = 0.014)
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regular clearance rate demonstrating exponential kinetics.
Actually our data showed that the closer the R2 value is to 1,
the patients tend to have better oncologic outcomes. Con-
versely, patients who demonstrated a randomized CEA
clearance pattern, for which R2 values were \0.5, showed
poor prognosis. In patients with randomized CEA clearance
pattern, there would be a higher likelihood of a persistent
CEA source or undefined mechanism to disturb of CEA
clearance, such as in the form of microscopic metastasis or a
newly formed CEA-producing tumor possibly resulting
from tumor seeding.
In stage III rectal cancer, R2 values were significant
prognostic values in OS and DFS by multivariate analysis
of prognostic factors, such as N-staging (P = 0.02,
P = 0.002, respectively). However, the single CEA values,
measured on postoperative days 7 and 30, did not have
more significance in DFS or OS in multivariate analysis
when analyzed with R2 values. The CEA value on
postoperative day 7 was significantly related to OS by
multivariate analysis but was not found to be related to
DFS, although it was significantly related to both by uni-
variate analysis. The CEA value obtained on postoperative
day 30 was significantly related to both OS and DFS by
univariate analysis but not by multivariate analysis. We
expected that postoperative CEA values would be less
capable of providing prognostic information compared
with exponential trend lines because they are representative
of one point in time and because the effective postoperative
sampling date and ideal cutoff value remain controversial.
Furthermore, a single CEA value obtained after tumor
resection has limited ability to reflect the change in tumor
biology as our study showed that the postoperative day 7
CEA did not have any more significance in DFS by mul-
tivariate analysis with the R2 value.
The gradient, calculated from the exponential curve, did
not have prognostic significance in DFS and OS in stages II
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FIG. 4 The disease-free survival (DFS) curves according to the R2
value in stage III rectal cancer. Group I was the exponential decrease
group compared with group II, the nonexponential decrease group. a
There was no significant difference between the two groups
(P = 0.098). The group was further divided into three groups: group
1 was the exponential decrease group; group 2 was the nearly
exponential decrease group; and group 3 was the randomized
clearance group. b Group 3 had significantly worse DFS than group
1 (P = 0.027)
TABLE 4 Multivariate analysis of risk factors for 5-year DFS and OS in stage III rectal cancer
Disease-free survival Overall survival
HR 95% Cl P value HR 95% CI P value
R2 value 2.467 0.029–0.735 0.020 0.110 0.027–0.459 0.002
POD 7 CEA (ng/ml) 0.566–3.356 0.480 1.243–6.407 0.013
B5 1.378 2.882
[5 1 1
POD 30 CEA (ng/ml) 0.781–6.702 0.131 0.567–4.078 0.413
B5 2.288 1.513
[5 1 1
Pathologic N stage 1.076–5.656 0.033 1.130–5.401 0.023
N1 2.467 2.470
N2 1 1
HR hazards ratio; CI confidence interval; CEA carcinoembryonic antigen; POD postoperative day
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and III rectal. In categorized evaluation of gradients, the
rapid rate of decline was significantly related to high pre-
operative CEA values, which averaged 45.2 ± 1.25 ng/ml.
Although there is no scientific evidence, there was some
consideration of whether the rapid rate of CEA clearance
would provide better oncologic outcomes. However, as our
data showed, the rate of CEA clearance was not related to
oncologic outcomes but was significantly related to the
preoperative CEA value (P \ 0.001). CEA clearance
velocity is known to be significantly influenced by the liver
function of individual patients;13 data suggest that one
more factor, preoperative CEA value, influences the
velocity of CEA clearance.
The limitations of our study are as follows: 1) the ret-
rospective nature of the investigation comprised of a small
patient population; 2) the limited number of data points of
serum CEA levels. More postoperative CEA values would
likely have resulted in greater significance of our results.
Despite these limitations, it is apparent from our data that
patients with random CEA clearance kinetics have poorer
oncologic outcomes compared with those with exponential
kinetics clearance. This study asserted the potential of
serum CEA clearance as a useful prognostic tool based on
clear evidence of biomolecular kinetics. The pattern of
CEA clearance using perioperative serum changes may
become an authentic and reliable prognostic method for
predicting both OS and DFS rates in rectal cancer with the
same clinical staging with the ultimate goal of designing
more tailored antitumor therapies for individual patients.
CONCLUSIONS
Serial measurement of perioperative serum CEA clear-
ance patterns during the preoperative and early and late
postoperative periods are important indicators for both OS
and DFS rates of patients with stage III rectal cancer with
high preoperative CEA levels. If the serum CEA level is
cleared via randomized kinetics, one must suspect the
possibility of micrometastasis or the regrowth of remnant
tumors due to the failure of complete tumor resection and
consider intensive follow-up or the addition of adjuvant
chemotherapy or radiation therapy.
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